(2023). Real-world evidence from the first online healthcare analytics platform-Livingstone. Validation of its descriptive epidemiology module. Plos Digit Health, 2, e0000310. http://doi.org/10.1371/journal.pdig.0000310
. S. Holden
First name
S.
Middle name
E.
Last name
Holden
(2013). The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). Child Adolesc Psychiatry Ment Health. http://doi.org/10.1186/1753-2000-7-34
. (2014). How many people inject insulin? UK estimates from 1991 to 2010. Diabetes Obes Metab. http://doi.org/10.1111/dom.12260
. (2014). Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab. http://doi.org/10.1111/dom.12302
. (2014). Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. http://doi.org/10.1111/dom.12354
. (2014). Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab. http://doi.org/10.1111/dom.12306
. (2015). Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab. http://doi.org/10.1111/dom.12412
. (2016). Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. PLoS One. http://doi.org/10.1371/journal.pone.0153594
. (2017). Prevalence, glucose control and relative survival of people with Type 2 diabetes in the UK from 1991 to 2013. Diabet Med. http://doi.org/10.1111/dme.13332
. (2017). Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.12916
.